



## BSW Formulary Update – July 2023

### New additions to BSWformulary and Formulary alignments

- [Doxycycline 40mg modified release capsules \(Efracea®\)](#) – added with **GREEN** TLS for the treatment of mild-severe papulopustular rosacea.
- [Morphine sulfate orodispersible tablets \(Actimorph®\)](#) – added with **GREEN** TLS for breakthrough pain in palliative care patients.
- [Carbetocin 100micrograms/ml ampoules](#) - added with **RED** TLS for prevention of uterine atony after caesarean section.
- [Gentamicin injection \(nebulised, unlicensed\) for non-CF bronchiectasis](#) – aligned with **RED** TLS for BSW.
- [Duloxetine 30mg and 60mg capsules](#) – aligned with **GREEN** TLS for all indications.

### New and Updated Shared Care Agreements and Prescribing Guidance

- **NEW** - [Finerenone \(Kerendia®\) for treatment of CKD in T2DM in adults](#) – Prescribing guidance to support the implementation of [NICE TA877](#). The TLS of finerenone has been assigned **AMBER following specialist\* initiation**. \*For this local guidance, a specialist could be a prescriber with a clinical interest in renal medicine/endocrinology and experience of treating CKD and could be a prescriber working in primary care. The NICE TA notes people who may be eligible for finerenone treatment may not always be receiving care in secondary care settings. NICE conclude that finerenone may initially be prescribed in secondary care but will likely be prescribed in primary care as experience grows. A review of TLS to GREEN will be considered by the APC once experience is gained locally.
- **UPDATED** – [Oral Nutrition Supplements \(ONS\) Formulary](#)
- **UPDATED** – [BSW Inflammatory Bowel Disease \(IBD\) Biologic Pathways](#)

### What the BSW CCG formulary team are currently working on

- Updating BSW Shared Care Agreements for subcutaneous methotrexate.
- Reviewing local emollient prescribing guidance for primary care.
- Working with local neurology specialists to review the Chronic Migraine Pathway and the Biological Treatment Pathway in line with recent and upcoming NICE technology appraisals for drugs used in management of migraine.
- Working with colleagues across RUH/SFT/GWH to update information in our Shared Care Agreement on blood monitoring in females using testosterone as part of HRT regimen.



Bath and North East Somerset,  
Swindon and Wiltshire Together

*The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email [bswicb.formulary@nhs.net](mailto:bswicb.formulary@nhs.net)*